</head> <body style="-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;margin:0;min-width:100%;padding:0;width:100%" data-bg-color="#E9EBF2" bgcolor="#E9EBF2">
CB Partner Webinar {{webinarsautomatedemailsthankyou::omeda}} #EVENTTITLE# {{webinarsautomatedemailsthankyou::round_table}} Exubrion Therapeutics, makers of Synovetin OA {{webinarsautomatedemailsthankyou::client_only_logo}} {{webinarsautomatedemailsthankyou::client_only_logo_self_hosted}} {{webinarsautomatedemailsthankyou::client_only_logo_alt}} {{webinarsautomatedemailsthankyou::client_only_logo_width}} {{webinarsautomatedemailsthankyou::client_only_logo_custom_css}} {{webinarsautomatedemailsthankyou::client_color}} {{webinarsautomatedemailsthankyou::supported_by}} We hope the information was helpful. Synovitis (ie, inflammation and thickening of the synovium) occurs as a component of arthritis and is likely a major source of pain in its early to middle stages. With synovitis, macrophages in the synovium produce proinflammatory cytokines, collagenase, and other hydrolytic enzymes that result in a catabolic environment and enhanced cartilage degeneration. Traditional treatment options (eg, conservative/medical, surgical) all have a place in the management of canine elbow dysplasia; however, none significantly change the inflammatory and catabolic joint environment. Limiting synovial inflammation may help limit or control elbow osteoarthritis- related pain. Synovetin OA (tin- 117m), a radioisotope of tin in a colloidal suspension, can be given intraarticularly on an outpatient basis and is a minimally invasive treatment strategy for decreasing synovitis and associated pain and lameness in dogs with elbow osteoarthritis, with a duration of effect up to 12 months. {{webinarsautomatedemailsthankyou::custom_printable_pdf_copy}} https://cdn.brief.vet/webinars/Exubrion/Exubrion+Therapeutics%2C+Top+5+Takeaways_FINAL.pdf {{webinarsautomatedemailsthankyou::custom_ce_certificate_copy}} https://cdn.brief.vet/webinars/Exubrion/Webinar+3/Understanding+and+Treating+Inflammation+that+Drives+Canine+OA%2C+LIVE+Certificate+6-11.pdf #AUDIENCEURL# {{webinarsautomatedemailsthankyou::remove_on_demand_text}}
Dear #FIRSTNAME#,
Thank you for attending our webinar, "{{webinarsautomatedemailsthankyou::webinar_title}}," sponsored by Exubrion Therapeutics, makers of Synovetin OA. We hope the information was helpful. Thank you for attending our webinar, "{{webinarsautomatedemailsthankyou::webinar_title}}." We hope the information was helpful.
Below you will find the Top 5 Takeaways from the webinar as well as your CE certificate.
Top 5 Takeaways
  1. Synovitis (ie, inflammation and thickening of the synovium) occurs as a component of arthritis and is likely a major source of pain in its early to middle stages.
  2. With synovitis, macrophages in the synovium produce proinflammatory cytokines, collagenase, and other hydrolytic enzymes that result in a catabolic environment and enhanced cartilage degeneration.
  3. Traditional treatment options (eg, conservative/medical, surgical) all have a place in the management of canine elbow dysplasia; however, none significantly change the inflammatory and catabolic joint environment.
  4. Limiting synovial inflammation may help limit or control elbow osteoarthritis- related pain.
  5. Synovetin OA (tin- 117m), a radioisotope of tin in a colloidal suspension, can be given intraarticularly on an outpatient basis and is a minimally invasive treatment strategy for decreasing synovitis and associated pain and lameness in dogs with elbow osteoarthritis, with a duration of effect up to 12 months.
Download a printable PDF of these takeaways.
Your CE Certificate
Download and complete your certificate here.
Feel free to pass this along to colleagues who may be interested.
If you would like to reference the on‑demand version of the event, click here.
Thanks again for attending,
The Clinician's Brief Team
The Exubrion Therapeutics, makers of Synovetin OA Team
</head> <body style="-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;margin:0;min-width:100%;padding:0;width:100%" data-bg-color="#E9EBF2" bgcolor="#E9EBF2">
Dear #FIRSTNAME#,
Thank you for attending our webinar, "{{webinarsautomatedemailsthankyou::webinar_title}}," sponsored by Exubrion Therapeutics, makers of Synovetin OA. We hope the information was helpful. Thank you for attending our webinar, "{{webinarsautomatedemailsthankyou::webinar_title}}." We hope the information was helpful.
Below you will find the Top 5 Takeaways from the webinar as well as your CE certificate.
Top 5 Takeaways
  1. Synovitis (ie, inflammation and thickening of the synovium) occurs as a component of arthritis and is likely a major source of pain in its early to middle stages.
  2. With synovitis, macrophages in the synovium produce proinflammatory cytokines, collagenase, and other hydrolytic enzymes that result in a catabolic environment and enhanced cartilage degeneration.
  3. Traditional treatment options (eg, conservative/medical, surgical) all have a place in the management of canine elbow dysplasia; however, none significantly change the inflammatory and catabolic joint environment.
  4. Limiting synovial inflammation may help limit or control elbow osteoarthritis- related pain.
  5. Synovetin OA (tin- 117m), a radioisotope of tin in a colloidal suspension, can be given intraarticularly on an outpatient basis and is a minimally invasive treatment strategy for decreasing synovitis and associated pain and lameness in dogs with elbow osteoarthritis, with a duration of effect up to 12 months.
Download a printable PDF of these takeaways.
Your CE Certificate
Download and complete your certificate here.
Feel free to pass this along to colleagues who may be interested.
If you would like to reference the on‑demand version of the event, click here.
Thanks again for attending,
The Clinician's Brief Team
The Exubrion Therapeutics, makers of Synovetin OA Team